EUVIMEDEUVIMED entdecken
Open Access

Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor Microenvironment

Hesam Khodadadi, Évila Lopes Salles, Ahmet Alptekin, Daniel Mehrabian iD, Martin Rutkowski, Ali S Arbab, W Andrew Yeudall, Jack C Yu, John C Morgan, David C Hess, Kumar Vaibhav, Krishnan M Dhandapani und 1 weitere

Cannabis & Cannabinoid Research · 01.10.2023 · 8 (5) · 824-834

DOI: 10.1089/can.2021.0098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cannabis & Cannabinoid Research, online erschienen am 09.10.2023. Verfasst von Hesam Khodadadi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, Georgia, USA. Hauptthemen laut MEDLINE: Glioblastoma, Cannabidiol, Brain Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Glioblastoma (GBM) is the most common invasive brain tumor composed of diverse cell types with poor prognosis. The highly complex tumor microenvironment (TME) and its interaction with tumor cells play important roles in the development, progression, and durability of GBM. Angiogenic and immune factors are two major components of TME of GBM; their interplay is a major determinant of tumor vascularization, immune profile, as well as immune unresponsiveness of GBM. Given the ineffectiveness of current standard therapies (surgery, radiotherapy, and concomitant chemotherapy) in managing patients with GBM, it is necessary to develop new ways of treating these lethal brain tumors. Targeting TME, altering tumor ecosystem may be a viable therapeutic strategy with beneficial effects for patients in their fight against GBM. Materials and Methods: Given the potential therapeutic effects of cannabidiol (CBD) in a wide spectrum of diseases, including malignancies, we tested, for the first time, whether inhalant CBD can inhibit GBM tumor growth using a well-established orthotopic murine model. Optical imaging, histology, immunohistochemistry, and flow cytometry were employed to describe the outcomes such as tumor progression, cancer cell signaling pathways, and the TME.

Results

Our findings showed that inhalation of CBD was able to not only limit the tumor growth but also to alter the dynamics of TME by repressing P-selectin, apelin, and interleukin (IL)-8, as well as blocking a key immune checkpoint—indoleamine 2,3-dioxygenase (IDO). In addition, CBD enhanced the cluster of differentiation (CD) 103 expression, indicating improved antigen presentation, promoted CD8 immune responses, and reduced innate Lymphoid Cells within the tumor.

Conclusion

Overall, our novel findings support the possible therapeutic role of inhaled CBD as an effective, relatively safe, and easy to administer treatment adjunct for GBM with significant impacts on the cellular and molecular signaling of TME, warranting further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCannabidiolBrain NeoplasmsHumansMiceAnimalsTumor MicroenvironmentEcosystemImmunity, InnateCell Line, TumorLymphocytes

Stichwörter der Autor:innen

CBDIDOP-selectinglioblastomaimmune checkpointtumor microenvironment

Substanzen

Cannabidiol

Autor:innen und Institutionen

  • Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Center for Excellence in Research, Scholarship and Innovation, Dental College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
  • Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Department of Neurosurgery and Medical College of Georgia, Augusta University, Augusta, Georgia, USA.
  • Department of Surgery, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

ORCID-Profile: Daniel Mehrabian, Babak Baban

Zitieren

APA

Khodadadi, H., Salles, É. L., Alptekin, A., Mehrabian, D., Rutkowski, M., Arbab, A. S., Yeudall, W. A., Yu, J. C., Morgan, J. C., Hess, D. C., Vaibhav, K., Dhandapani, K. M., & Baban, B. (2023). Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor Microenvironment. Cannabis & Cannabinoid Research, 8(5), 824-834. https://doi.org/10.1089/can.2021.0098

Vancouver

Khodadadi H, Salles ÉL, Alptekin A, Mehrabian D, Rutkowski M, Arbab AS, et al. Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor Microenvironment. Cannabis & Cannabinoid Research. 2023;8(5):824-834. doi:10.1089/can.2021.0098

BibTeX
@article{Khodadadi2023,
  author = {Khodadadi, Hesam and Salles, Évila Lopes and Alptekin, Ahmet and Mehrabian, Daniel and Rutkowski, Martin and Arbab, Ali S and Yeudall, W Andrew and Yu, Jack C and Morgan, John C and Hess, David C and Vaibhav, Kumar and Dhandapani, Krishnan M and Baban, Babak},
  title = {Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor Microenvironment},
  journal = {Cannabis & Cannabinoid Research},
  year = {2023},
  volume = {8},
  number = {5},
  pages = {824--834},
  doi = {10.1089/can.2021.0098}
}
Kostenlos starten →